The drug – a selective muscarinic M4 receptor ... an already-approved muscarinic antagonist designed to reduce M1/M4-related side effects in the peripheral nervous system. Meanwhile, Sosei ...

Karuna’s drug is thought to exert its antipsychotic effects through muscarinic M1 and M4 receptors in the central nervous system, targeted by xanomeline, while trospium prevents side effects by ...

Another area finally showing promise are the muscarinic receptors in neuropsychiatric disorders 4. Drug developers have been trying to crack these receptors for decades, but the similarity between ...

Cholinergic drugs (acetylcholine and methacholine ... both events explain the increase in airway resistance. Muscarinic (M) receptors involved in the airway tone regulation are as follows ...

Umeclidinium is a long-acting muscarinic antagonist, which is often referred ... The pharmacologic effects of beta2-adrenergic agonist drugs, including vilanterol, are at least in part ...

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress ...

NXE-0048149 is under clinical development by Nxera Pharma and currently in Phase I for Psychosis. According to GlobalData, Phase I drugs for Psychosis have a 59% phase transition success rate (PTSR) ...